A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study).
Liran TiosanoRita EhrlichYoreh BarakHaya KatzRussell PokroyTarek JaouniJaime LevyJoel HanhartOri SegalShiri ShulmanMichaella GoldsteinItay ChowersPublished in: Eye (London, England) (2020)
Eyes with persistent DMO following initial bevacizumab therapy had a marked reduction in macular thickness and improved visual acuity following 1 year of treatment with intravitreal aflibercept. Less than half of the patients met eligibility criteria for extension of the treatment interval; for these patients, the treat-and-extend regimen resulted in a maximum treatment interval of 10 weeks during the first year.
Keyphrases
- end stage renal disease
- optical coherence tomography
- diabetic retinopathy
- ejection fraction
- age related macular degeneration
- newly diagnosed
- chronic kidney disease
- stem cells
- peritoneal dialysis
- vascular endothelial growth factor
- prognostic factors
- mesenchymal stem cells
- patient reported outcomes
- replacement therapy
- smoking cessation